BRIEF-Biogen's Alzheimer drug Aducanumab Accepted into EMA's PRIME Program

* Biogen's Investigational Alzheimer's Disease Treatment Aducanumab Accepted Into European Medicines Agency's Prime Program
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.